DK2563385T3 - Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis - Google Patents

Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis

Info

Publication number
DK2563385T3
DK2563385T3 DK11778000.7T DK11778000T DK2563385T3 DK 2563385 T3 DK2563385 T3 DK 2563385T3 DK 11778000 T DK11778000 T DK 11778000T DK 2563385 T3 DK2563385 T3 DK 2563385T3
Authority
DK
Denmark
Prior art keywords
soluble
treatment
methods
reumatoid arthritis
reumatoid
Prior art date
Application number
DK11778000.7T
Other languages
Danish (da)
English (en)
Inventor
Xincheng Zheng
Wei Wu
Yang Liu
Pan Zheng
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Application granted granted Critical
Publication of DK2563385T3 publication Critical patent/DK2563385T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK11778000.7T 2010-04-28 2011-04-28 Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis DK2563385T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
DK2563385T3 true DK2563385T3 (da) 2017-11-06

Family

ID=44903987

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11778000.7T DK2563385T3 (da) 2010-04-28 2011-04-28 Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis

Country Status (17)

Country Link
US (1) US8808697B2 (cg-RX-API-DMAC7.html)
EP (3) EP2563385B1 (cg-RX-API-DMAC7.html)
JP (5) JP5899206B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130086126A (cg-RX-API-DMAC7.html)
CN (2) CN105381451B (cg-RX-API-DMAC7.html)
AU (1) AU2011248540B2 (cg-RX-API-DMAC7.html)
CA (1) CA2795823C (cg-RX-API-DMAC7.html)
DK (1) DK2563385T3 (cg-RX-API-DMAC7.html)
EA (2) EA027735B1 (cg-RX-API-DMAC7.html)
ES (2) ES2645262T3 (cg-RX-API-DMAC7.html)
IL (1) IL222739A0 (cg-RX-API-DMAC7.html)
NO (1) NO2563385T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ603196A (cg-RX-API-DMAC7.html)
PL (2) PL3260128T3 (cg-RX-API-DMAC7.html)
PT (2) PT3260128T (cg-RX-API-DMAC7.html)
SG (1) SG184907A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011139820A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CN107531772B (zh) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Cd24用于降低低密度脂蛋白胆固醇水平的用途
SG11201806338SA (en) * 2016-02-02 2018-08-30 Oncoimmune Inc Use of cd24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
CN110461353A (zh) * 2017-03-07 2019-11-15 肿瘤免疫股份有限公司 可溶性cd24用于治疗系统性红斑狼疮的使用方法
KR20200034957A (ko) * 2017-05-15 2020-04-01 온코이뮨, 아이앤씨. 신경 보호 및 재수초화를 위한 가용성 cd24의 사용 방법
CN110799206A (zh) * 2017-05-22 2020-02-14 肿瘤免疫股份有限公司 使用可溶性cd24治疗癌症疗法中免疫相关不良事件的方法
AU2019231191A1 (en) * 2018-03-05 2020-09-03 Institute Of Biophysics, Chinese Academy Of Sciences Methods of use of soluble CD24 for treating acquired immune deficiency syndrome (HIV/AIDS)
TWI835794B (zh) * 2018-05-14 2024-03-21 美商昂科Ｃ４公司 抗cd24組合物及其用途
EP3801773A4 (en) * 2018-06-04 2022-03-16 Oncoimmune, Inc. METHOD OF USE OF CD24 FOR PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE AND MUCOSITIS
EP4017508A1 (en) * 2019-08-23 2022-06-29 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
EP4408862A4 (en) * 2021-09-28 2025-11-12 Acroimmune Guangzhou Biotech Ltd Fusion proteins including the O71 core peptide and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
HUP0303171A2 (hu) * 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
CA2453406A1 (en) * 2001-07-13 2003-01-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for reducing immunogenicity of polypeptides
CA2505601C (en) * 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
NZ587776A (en) * 2003-04-09 2012-03-30 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
EP1706507A4 (en) * 2003-11-26 2008-02-20 Univ Ohio State Res Found THE RISK AND PROGRESSION OF MULTIPLE SCLEROSIS PREDICTING POLYMORPHS CD24 GENOTYPES
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US20060160220A1 (en) * 2004-11-12 2006-07-20 Iogenetics Retroviral vectors with introns

Also Published As

Publication number Publication date
PL3260128T3 (pl) 2021-02-08
CA2795823A1 (en) 2011-11-10
US8808697B2 (en) 2014-08-19
CN105381451B (zh) 2021-03-09
NZ603196A (en) 2014-07-25
EP2563385B1 (en) 2017-08-02
HK1222554A1 (zh) 2017-07-07
HK1176007A1 (zh) 2013-07-19
WO2011139820A1 (en) 2011-11-10
JP6888221B2 (ja) 2021-06-16
JP2015187162A (ja) 2015-10-29
CN105381451A (zh) 2016-03-09
CA2795823C (en) 2019-06-04
EP3260128A1 (en) 2017-12-27
ES2826445T3 (es) 2021-05-18
JP5899206B2 (ja) 2016-04-06
JP2017057216A (ja) 2017-03-23
PT2563385T (pt) 2017-11-10
EA036805B8 (ru) 2021-02-25
KR20130086126A (ko) 2013-07-31
PL2563385T3 (pl) 2018-04-30
IL222739A0 (en) 2012-12-31
JP2019151655A (ja) 2019-09-12
SG184907A1 (en) 2012-11-29
EP2563385A4 (en) 2013-10-02
CN102869369B (zh) 2016-05-18
EP3845238A1 (en) 2021-07-07
EA036805B1 (ru) 2020-12-23
EA201790538A3 (ru) 2017-11-30
CN102869369A (zh) 2013-01-09
JP2018127493A (ja) 2018-08-16
AU2011248540B2 (en) 2014-11-20
ES2645262T3 (es) 2017-12-04
PT3260128T (pt) 2020-10-22
EA027735B1 (ru) 2017-08-31
EP2563385A1 (en) 2013-03-06
WO2011139820A8 (en) 2013-02-07
JP6062502B2 (ja) 2017-01-18
NO2563385T3 (cg-RX-API-DMAC7.html) 2017-12-30
JP6526872B2 (ja) 2019-06-05
EA201790538A2 (ru) 2017-07-31
EA201290961A1 (ru) 2013-04-30
JP2013527168A (ja) 2013-06-27
US20130136739A1 (en) 2013-05-30
EP3260128B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
DK2563385T3 (da) Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2854769T3 (da) Fremgangsmåder til behandling af artritis
DK2717941T3 (da) Behandling af cancer
DK2553113T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
DK2753334T3 (da) Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK2785349T4 (da) Kombinationsbehandling af cancer
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
FI20125358L (fi) Menetelmä ligniinin reaktiivisuuden lisäämiseksi
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2683384T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2987507T3 (da) Fremgangsmåder til behandling af degenerative knogletilstande
DK2531526T3 (da) Fremgangsmåde til opnåelse af antistoffer
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK3299356T3 (da) Fremgangsmåde til fremstilling af pleuromutiliner
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
DK3138916T3 (da) Immunogen sammensætning
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK2552963T3 (da) Humaniserede antistoffer mod CXCR4 til behandling af cancer